GSA Capital Partners LLP Has $852,000 Holdings in Treace Medical Concepts, Inc. $TMCI

GSA Capital Partners LLP raised its position in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 212.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 347,755 shares of the company’s stock after purchasing an additional 236,477 shares during the quarter. GSA Capital Partners LLP’s holdings in Treace Medical Concepts were worth $852,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMCI. AQR Capital Management LLC acquired a new position in Treace Medical Concepts in the first quarter valued at about $491,000. Millennium Management LLC boosted its position in Treace Medical Concepts by 35.3% in the first quarter. Millennium Management LLC now owns 444,887 shares of the company’s stock valued at $3,733,000 after buying an additional 116,114 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Treace Medical Concepts by 133,241.9% in the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock valued at $243,000 after buying an additional 41,305 shares in the last quarter. Invesco Ltd. boosted its position in Treace Medical Concepts by 18.6% in the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock valued at $88,000 after buying an additional 2,362 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Treace Medical Concepts by 256.2% in the second quarter. Marshall Wace LLP now owns 135,877 shares of the company’s stock valued at $799,000 after buying an additional 97,729 shares in the last quarter. 84.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO John T. Treace bought 61,750 shares of Treace Medical Concepts stock in a transaction dated Thursday, May 14th. The shares were bought at an average cost of $2.62 per share, for a total transaction of $161,785.00. Following the completion of the transaction, the chief executive officer owned 7,158,313 shares of the company’s stock, valued at approximately $18,754,780.06. This trade represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have purchased 153,763 shares of company stock worth $375,667 in the last quarter. 23.42% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TMCI shares. Wall Street Zen upgraded shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research report on Monday, April 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Finally, Lake Street Capital reduced their price target on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Treace Medical Concepts has a consensus rating of “Reduce” and a consensus target price of $4.77.

Treace Medical Concepts Price Performance

Shares of TMCI stock opened at $2.78 on Friday. Treace Medical Concepts, Inc. has a 1 year low of $1.17 and a 1 year high of $7.78. The firm’s 50 day moving average is $1.82 and its 200-day moving average is $2.36. The firm has a market capitalization of $180.34 million, a price-to-earnings ratio of -2.87 and a beta of 1.10. The company has a current ratio of 3.58, a quick ratio of 2.53 and a debt-to-equity ratio of 0.72.

Treace Medical Concepts (NASDAQ:TMCI) last announced its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. The company had revenue of $47.20 million for the quarter, compared to analyst estimates of $45.96 million. Sell-side analysts forecast that Treace Medical Concepts, Inc. will post -0.88 EPS for the current fiscal year.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.